2024
P2X 7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study
Lehto J, Aarnio R, Tuisku J, Sucksdorff M, Koivumäki E, Nylund M, Helin S, Rajander J, Danon J, Gilchrist J, Kassiou M, Oikonen V, Airas L. P2X 7-receptor binding in new-onset and secondary progressive MS – a [11C]SMW139 PET study. EJNMMI Research 2024, 14: 123. PMID: 39636350, PMCID: PMC11621262, DOI: 10.1186/s13550-024-01186-3.Peer-Reviewed Original ResearchPerilesional rimTracer bindingDisability progressionMS patientsMS brainsLesion rimWhite matterProgressive MS patientsPro-inflammatory microgliaRelapsed patientsSmoldering inflammationT1 lesionsMales compared to femalesNew-onsetProgressive patientsTracer uptakeParent tracerP2XDisease durationProgressive MSHealthy controlsPatientsPET studiesPerilesional areaFree fractionThe Alopecia Areata Severity and Morbidity Index (ASAMI) Study
Group A, Moussa A, Bennett M, Wall D, Meah N, York K, Bokhari L, Asfour L, Rees H, Abraham L, Asz-Sigall D, Basmanav F, Bergfeld W, Betz R, Bhoyrul B, Blume-Peytavi U, Callender V, Chitreddy V, Combalia A, Cotsarelis G, Craiglow B, Dhurat R, Donovan J, Doroshkevich A, Eisman S, Farrant P, Ferrando J, Gadzhigoroeva A, Green J, Grimalt R, Harries M, Hordinsky M, Irvine A, Jolliffe V, Kaiumov S, King B, Lee J, Lee W, Li J, Lortkipanidze N, McMichael A, Mesinkovska N, Messenger A, Mirmirani P, Olsen E, Orlow S, Ovcharenko Y, Piraccini B, Pirmez R, Rakowska A, Reygagne P, Rudnicka L, Corralo D, Senna M, Shapiro J, Sharma P, Siliuk T, Starace M, Suchonwanit P, Takwale A, Tosti A, Vañó-Galván S, Visser W, Vogt A, Wade M, Yip L, Zhou C, Sinclair R. The Alopecia Areata Severity and Morbidity Index (ASAMI) Study. JAMA Dermatology 2024, 160: 341-350. PMID: 38324292, DOI: 10.1001/jamadermatol.2023.5869.Peer-Reviewed Original ResearchSurvey roundsTool scorePerspectives of patientsDisease impactDelphi study designHistory of anxietyImpaired quality of lifeQuality of lifeScalp hair lossIdentified various determinantsSeverity of Alopecia Tool scoreAssessment ScaleVideo conference meetingsGlobal Assessment ScaleStudy designImpaired qualitySurvey studyVideo conferencing softwareHair lossSuicidal ideationAA severityConference meetingsAlopecia areataSystemic treatmentDisease durationExploring Factors That Influence Postexercise Glycemia in Youth With Type 1 Diabetes in the Real World: The Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) Study.
Sherr J, Bergford S, Gal R, Clements M, Patton S, Calhoun P, Beaulieu L, Riddell M. Exploring Factors That Influence Postexercise Glycemia in Youth With Type 1 Diabetes in the Real World: The Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) Study. Diabetes Care 2024, 47: 849-857. PMID: 38412033, DOI: 10.2337/dc23-2212.Peer-Reviewed Original ResearchParticipants self-reported physical activitySelf-reported physical activityPostexercise recovery periodEvent-level factorsExercise sessionsPhysical activitySedentary dayExercise studiesSupport exerciseExerciseDelivery modalitiesSD ageType 1 diabetesHemoglobin A1cPostexercisePump useShorter disease durationDecision support toolGlucose dataRecovery periodHbA1cDisease durationHypoglycemia riskInsulin delivery modalityHypoglycemia ratesReal-World Tralokinumab Use in Dupilumab-Experienced Patients: A Eetrospective Multi-Center Case Series
Herman E, Burgy J, Shahriari M. Real-World Tralokinumab Use in Dupilumab-Experienced Patients: A Eetrospective Multi-Center Case Series. SKIN The Journal Of Cutaneous Medicine 2024, 8: s321. DOI: 10.25251/skin.8.supp.321.Peer-Reviewed Original ResearchTreated with dupilumabAtopic dermatitisDupilumab treatmentTralokinumab treatmentCase seriesSafety profileLong-term disease controlHead-to-head studiesDiscontinued dupilumab treatmentTreated with topicalMulti-center case seriesDuration of treatmentLack of efficacyEvaluate clinical findingsBiologic dupilumabHerpes labialisNRS scoresAdult patientsClinical findingsDupilumabTreatment optionsEffective therapyTralokinumabDisease durationJoint pain
2023
The Acute Effects of Real-World Physical Activity on Glycemia in Adolescents With Type 1 Diabetes: The Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) Study.
Riddell M, Gal R, Bergford S, Patton S, Clements M, Calhoun P, Beaulieu L, Sherr J. The Acute Effects of Real-World Physical Activity on Glycemia in Adolescents With Type 1 Diabetes: The Type 1 Diabetes Exercise Initiative Pediatric (T1DEXIP) Study. Diabetes Care 2023, 47: 132-139. PMID: 37922335, DOI: 10.2337/dc23-1548.Peer-Reviewed Original ResearchConceptsReal-world physical activityPhysical activityType 1Pediatric studiesHeart rateLower baseline HbA1c levelsReal-world observational studySelf-reported physical activityBaseline HbA1c levelsShorter disease durationPeak heart rateType 1 diabetesSelf-management strategiesDisease durationHbA1c levelsMedian durationLess hypoglycemiaLower BMIAcute effectsContinuous glucose monitoring dataObservational studyFood intakeEvent-level factorsInsulin dosingActive adolescentsClinical Phenotypes of Patients With Systemic Sclerosis With Distinct Molecular Signatures in Skin
Yang M, Goh V, Lee J, Espinoza M, Yuan Y, Carns M, Aren K, Chung L, Khanna D, McMahan ZH, Agrawal R, Nelson L, Shah SJ, Whitfield ML, Hinchcliff M. Clinical Phenotypes of Patients With Systemic Sclerosis With Distinct Molecular Signatures in Skin. Arthritis Care & Research 2023, 75: 1469-1480. PMID: 35997480, PMCID: PMC9947190, DOI: 10.1002/acr.24998.Peer-Reviewed Original ResearchConceptsRadiographic interstitial lung diseaseInterstitial lung diseaseHigher mRSSSSc patientsSerum autoantibodiesClinical phenotypeHealthy participantsScl-70 antibodyPresent multicenter studySimilar disease durationSystemic sclerosis patientsDistinct clinical phenotypesSkin gene expressionValuable clinical informationDcSSc patientsDisease durationIdentifies patientsSystemic sclerosisSclerosis patientsMulticenter studyLung diseaseSkin fibrosisSimilar prevalenceClinical dataMultivariable modeling
2022
Shape analysis of subcortical structures in obsessive‐compulsive disorder and the relationship with comorbid anxiety, depression, and medication use: A meta‐analysis by the OCD Brain Imaging Consortium
Fouche J, Groenewold N, Sevenoaks T, Heany S, Lochner C, Alonso P, Batistuzzo M, Cardoner N, Ching C, de Wit S, Gutman B, Hoexter M, Jahanshad N, Kim M, Kwon J, Mataix‐Cols D, Menchon J, Miguel E, Nakamae T, Phillips M, Pujol J, Sakai Y, Yun J, Soriano‐Mas C, Thompson P, Yamada K, Veltman D, van den Heuvel O, Stein D. Shape analysis of subcortical structures in obsessive‐compulsive disorder and the relationship with comorbid anxiety, depression, and medication use: A meta‐analysis by the OCD Brain Imaging Consortium. Brain And Behavior 2022, 12: e2755. PMID: 36106505, PMCID: PMC9575597, DOI: 10.1002/brb3.2755.Peer-Reviewed Original ResearchConceptsCaudate nucleusHealthy controlsOCD patientsComorbid depressionMedication statusComorbid anxietySubcortical shapeSignificant differencesDeep gray matter structuresRight caudate nucleusCo-morbid anxietyLeft caudate nucleusObsessive-compulsive disorder patientsSubcortical brain morphologyGray matter structuresDisease durationMedication useObsessive-compulsive disorderSubgroup analysisBrain MRINucleus accumbensDisorder patientsPatientsBrain volumePutamenA genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis
Franks JM, Toledo DM, Martyanov V, Wang Y, Huang S, Wood TA, Spino C, Chung L, Denton C, Derrett-Smith E, Gordon JK, Spiera R, Domsic R, Hinchcliff M, Khanna D, Whitfield ML. A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis. Rheumatology 2022, 62: 19-28. PMID: 35751592, PMCID: PMC9788818, DOI: 10.1093/rheumatology/keac344.Peer-Reviewed Original ResearchConceptsMolecular subsetsIntrinsic subsetInflammatory subsetBaseline demographicsSSc patientsWhite/Caucasian patientsBaseline clinical demographicsAverage disease durationRodnan skin scoreAfrican American/BlackASSET trialUnique gene expression signatureDisease durationGene expression signaturesClinical demographicsParticipant seraSkin scoreSystemic sclerosisValidation cohortClinical variablesCaucasian patientsSpecific therapyAmerican/BlackSkin biopsiesDisease pathogenesisSex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry
Goldburg S, Chen R, Langholff W, Lafferty K, Gooderham M, de Jong E, Strober B. Sex Differences in Moderate to Severe Psoriasis: Analysis of the Psoriasis Longitudinal Assessment and Registry. Journal Of Psoriasis And Psoriatic Arthritis 2022, 7: 132-139. PMID: 39296535, PMCID: PMC11361528, DOI: 10.1177/24755303221099848.Peer-Reviewed Original ResearchPsoriasis Longitudinal AssessmentDisease characteristicsDermatology Life Quality Index scoresDisease severitySystemic therapy-naïve patientsLife Quality Index scoresLongitudinal assessmentPhysician global assessmentSystemic steroid therapyLifestyle risk factorsTherapy-naïve patientsNonmelanoma skin cancerObjective disease severityBody surface areaHistory of anxietyQuality Index scoresQuality of lifeChi-square testPsoriasis characteristicsSteroid therapySevere psoriasisTherapy-naïveDisease durationBiologic-naïvePatient characteristicsCOMPARISON OF THE INFLAMMATORY BOWEL DISEASES PHENOTYPE AND COURSE IN THE ELDERLY- AND EARLY-ONSET PATIENTS
Saberzadeh-Ardestani B, Anushiravani A, Khosravi B, Vahedi H, Malekzadeh M, Alatab S, Sadeghi A, Sima A, Malekzadeh R. COMPARISON OF THE INFLAMMATORY BOWEL DISEASES PHENOTYPE AND COURSE IN THE ELDERLY- AND EARLY-ONSET PATIENTS. Inflammatory Bowel Diseases 2022, 28: s72-s72. DOI: 10.1093/ibd/izac015.117.Peer-Reviewed Original ResearchElderly-onset inflammatory bowel diseaseInflammatory bowel diseaseInflammatory bowel disease patientsAge of diagnosisIBD-related surgeryRelative risk of outcomesRisk of outcomesCrohn's diseaseUlcerative colitisDisease durationPatient ageRelative riskUC patientsDisease activityExtraintestinal manifestationsElderly-onset IBD patientsEarly-onsetAnti-tumor necrosis factorPrevalence of extraintestinal manifestationsRisk of active diseaseEarly-onset inflammatory bowel diseaseRisk of stricture formationAnti-TNF useRetrospective cohort studyAssociated with higher usePREDICTORS OF CLINICAL RELAPSE AMONG PATIENTS WITH ULCERATIVE COLITIS IN ENDO-HISTOLOGIC REMISSION
Zeina T, Gandhi S, Mittal A, Levy A, Weinstock J, Jangi S. PREDICTORS OF CLINICAL RELAPSE AMONG PATIENTS WITH ULCERATIVE COLITIS IN ENDO-HISTOLOGIC REMISSION. Inflammatory Bowel Diseases 2022, 28: s47-s48. DOI: 10.1093/ibd/izac015.073.Peer-Reviewed Original ResearchRisk of relapseCumulative risk of relapseRisk of clinical relapseDeep remissionHistological remissionClinical relapseUlcerative colitisDisease durationEndoscopic remissionCumulative riskMedian follow-up timeDuration of follow-upPredictive of clinical relapseMedian disease durationFollow-up timeRetrospective cohort studyPredictors of relapseMayo endoscopic scoreTufts Medical CenterPatient-reported outcomesMedian ageRelapse rateRelapse riskEndoscopic scoreElectronic medical recordsWorsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic
Levit E, Cohen I, Dahl M, Edwards K, Weinstock-Guttman B, Ishikawa T, Kavak K, Leavitt V, Nelson K, Onomichi K, Bar-Or A, Perrone C, Riley C, Venkatesh S, De Jager PL, Xia Z, Longbrake EE, Collaborative M. Worsening physical functioning in patients with neuroinflammatory disease during the COVID-19 pandemic. Multiple Sclerosis And Related Disorders 2022, 58: 103482. PMID: 35016114, PMCID: PMC8742609, DOI: 10.1016/j.msard.2021.103482.Peer-Reviewed Original ResearchConceptsPhysical functionDepression scoresCOVID-19 pandemicPhysical disabilityNeurological inflammatory diseasesMajor academic medical centerAcademic medical centerHigher baseline levelsLack of diseaseDisease durationStudy entryTherapy useNeuroinflammatory diseasesMale genderInflammatory diseasesPhysical functioningMedical CenterMood symptomsDepressive symptomsSmall cohortBaseline levelsSerial surveysSignificant depressionOlder ageWorse depression
2021
Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis
Murphy MJ, Gruenstein D, Wang A, Peterson D, Levitt J, King B, Damsky W. Treatment of Persistent Erythema Multiforme With Janus Kinase Inhibition and the Role of Interferon Gamma and Interleukin 15 in Its Pathogenesis. JAMA Dermatology 2021, 157: 1477-1482. PMID: 34757416, PMCID: PMC8581795, DOI: 10.1001/jamadermatol.2021.4084.Peer-Reviewed Original ResearchConceptsPersistent erythema multiformeErythema multiformeJanus kinase (JAK) inhibitionBiopsy specimensInterleukin-15Interferon gammaMajor tertiary referral centreImportant cytokine mediatorMean disease durationMarked clinical improvementTertiary referral centerRetrospective case seriesCase series studySkin biopsy specimensMultiple treatment approachesKinase inhibitionClinical improvementDisease durationReferral centerConsecutive patientsTofacitinib treatmentCase seriesCytokine mediatorsFemale patientsRNA sequencingAlterations of the serum and CSF ferritin levels and the diagnosis and prognosis of amyotrophic lateral sclerosis
Paydarnia P, Mayeli M, Shafie M, Agah E, Hasani S, Jazani M, Sarraf P. Alterations of the serum and CSF ferritin levels and the diagnosis and prognosis of amyotrophic lateral sclerosis. ENeurologicalSci 2021, 25: 100379. PMID: 34869924, PMCID: PMC8626833, DOI: 10.1016/j.ensci.2021.100379.Peer-Reviewed Original ResearchSerum ferritin levelsCSF ferritin levelsFerritin levelsDisease progression rateDisease durationPrognosis of amyotrophic lateral sclerosisDiagnosis of ALCSF of patientsDiagnostic challengePrognostic utilityControl patientsProgression rateALS patientsExclusion criteriaSerumELISA methodPatientsPotential biomarkersAmyotrophic lateral sclerosisCSFALS casesDiseaseDiagnosisLateral sclerosisAlterationsEffect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis
Reich K, Mrowietz U, Menter A, Griffiths C, Bagel J, Strober B, Gomez N, Shi R, Guerette B, Lebwohl M. Effect of baseline disease severity on achievement of treatment target with apremilast: results from a pooled analysis. Journal Of The European Academy Of Dermatology And Venereology 2021, 35: 2409-2414. PMID: 34255891, DOI: 10.1111/jdv.17520.Peer-Reviewed Original ResearchConceptsDermatology Life Quality IndexWeek 32Treatment targetsPooled analysisNail Psoriasis Severity IndexGlobal assessmentPhysician global assessmentSevere plaque psoriasisBaseline disease severitySeverity IndexPsoriasis Severity IndexLong-term outcomesLife Quality IndexSevere skin diseaseImportant clinical conceptsESTEEM 1Plaque psoriasisDisease durationMost patientsPsoriasis AreaModerate diseasePsoriasis severityDisease characteristicsPsoriasis guidelinesSubgroup analysisIn vivo evidence of differential frontal cortex metabolic abnormalities in progressive and relapsing‐remitting multiple sclerosis
Swanberg KM, Prinsen H, DeStefano K, Bailey M, Kurada AV, Pitt D, Fulbright RK, Juchem C. In vivo evidence of differential frontal cortex metabolic abnormalities in progressive and relapsing‐remitting multiple sclerosis. NMR In Biomedicine 2021, 34: e4590. PMID: 34318959, DOI: 10.1002/nbm.4590.Peer-Reviewed Original ResearchConceptsProgressive multiple sclerosisRelapsing-remitting multiple sclerosisMultiple sclerosis patientsMultiple sclerosisDisease durationSclerosis patientsRelapsing-remitting multiple sclerosis patientsSignificant negative correlationAvailable disease-modifying therapiesFrontal cortex metabolismH-MRS protocolDisease-modifying therapiesHealthy control adultsN-acetyl aspartateCross-sectional analysisCortex metabolismMetabolic abnormalitiesΓ-aminobutyric acidMetabolites glutamateFrontal cortexSclerosisNegative correlationControl adultsGABAProton MRSLarge‐Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis
Bellocchi C, Ying J, Goldmuntz EA, Keyes‐Elstein L, Varga J, Hinchcliff ME, Lyons MA, McSweeney P, Furst DE, Nash R, Crofford LJ, Welch B, Goldin JG, Pinckney A, Mayes MD, Sullivan KM, Assassi S. Large‐Scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis. Arthritis & Rheumatology 2021, 73: 660-670. PMID: 33131208, PMCID: PMC8005427, DOI: 10.1002/art.41570.Peer-Reviewed Original ResearchConceptsDiffuse cutaneous systemic sclerosisInterstitial lung diseaseSerum protein profilesHealthy control subjectsControl subjectsSex-matched healthy control subjectsRodnan skin thickness scoreSevere interstitial lung diseaseCutaneous systemic sclerosisMean disease durationDiffuse cutaneous SScWhole blood gene expression profilingSkin thickness scoreBlood gene expression profilingPeripheral blood cellsCancer antigen 15Epidermal growth factor receptorSoluble epidermal growth factor receptorSerum proteinsGrowth factor receptorDisease activityDisease durationSystemic sclerosisCutaneous SScImmunosuppressive agents
2020
Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow‐ups and predictors of achieving treatment target
Xiang Y, Wang Q, Li H, Duan X, Fang Y, Yang P, Li Q, Wu R, Huo Y, Shi X, Wu Z, Wang Y, Jiang N, Hsieh E, Li M, Tian X, Zeng X, co‐authors C. Chinese registry of rheumatoid arthritis (CREDIT): III. The transition of disease activity during follow‐ups and predictors of achieving treatment target. International Journal Of Rheumatic Diseases 2020, 23: 1719-1727. PMID: 33034424, DOI: 10.1111/1756-185x.13996.Peer-Reviewed Original ResearchConceptsBiologic disease-modifying anti-rheumatic drugsDisease activityTreatment responseChinese RegistryRheumatoid arthritisDisease-modifying anti-rheumatic drugsBaseline Disease Activity ScoreConventional DMARD therapyLower baseline DAS28Baseline disease activityDisease Activity ScoreAnti-rheumatic drugsBaseline DAS28DMARD therapyLDA ratesPrednisolone usageSynthetic DMARDsEarly RADisease durationActivity scoreTreatment strategiesTreatment targetsYounger agePatientsBaselineAltered Systemic and Intestinal IgA Immune Responses in Individuals With Type 1 Diabetes
Huang J, Huang G, Li X, Hu F, Xie Z, Xiao Y, Luo S, Chao C, Guo K, Wong FS, Zhou Z, Wen L. Altered Systemic and Intestinal IgA Immune Responses in Individuals With Type 1 Diabetes. The Journal Of Clinical Endocrinology & Metabolism 2020, 105: dgaa590. PMID: 32860693, PMCID: PMC7549925, DOI: 10.1210/clinem/dgaa590.Peer-Reviewed Original ResearchConceptsIgA-bound bacteriaType 1 diabetesHealthy control individualsIgA immune responseControl individualsIgA immunityAutoantibody titersIgA concentrationsImmune responseType 1 diabetes patientsΒ-cell autoimmunityLonger disease durationSerum IgA concentrationNovel therapeutic targetEnzyme-linked immunosorbentDisease durationIgA levelsDiabetes patientsDiabetes displayGut homeostasisBlood samplesOral cavityTherapeutic targetDiabetesHost immunitySacral Nerve Stimulation in Parkinson's Disease Patients With Overactive Bladder Symptoms
Greenberg DR, Sohlberg EM, Zhang CA, Santini VE, Comiter CV, Enemchukwu EA. Sacral Nerve Stimulation in Parkinson's Disease Patients With Overactive Bladder Symptoms. Urology 2020, 144: 99-105. PMID: 32681915, DOI: 10.1016/j.urology.2020.06.063.Peer-Reviewed Original ResearchConceptsSacral nerve stimulationOveractive bladder symptomsPD patientsParkinson's disease patientsDisease patientsBladder symptomsNerve stimulationHigh maximal urethral closure pressureMaximal urethral closure pressurePost-void residual volumeStage IILevodopa equivalent daily dosePD disease durationStage I trialVoids/dayStage I patientsUrethral closure pressureEquivalent daily doseMale PD patientsBody mass indexLong-term outcomesSafety of treatmentRate of progressionLatest clinicDisease duration
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply